The final results had been difficult by uneven distribution of ApoE4 carriers concerning placebo and remedy groups, which was brought on by an EMA ask for throughout the trial. A subgroup Evaluation, introduced at CTAD, suggested that the cure benefit was not due to this imbalance (Nov 2018 meeting news). https://buytofidencetocilizumab-b51727.bloguetechno.com/article-under-review-63273103